IN THE CLAIMS:

Please amend claims 51, 62, and 73 in accordance with 37 C.F.R. § 1.121, as follows:

- 50. (Original) A pharmaceutical composition for use in breast cancer therapy in humans, said composition comprising:
- (a) at least one antineoplastic agent selected from the group consisting of epirubicin and docetaxel, and a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, or combinations thereof; and
- (b) aromatase inhibitor exemestane and a pharmaceutically acceptable carrier, pharmaceutically acceptable diluent, or combination thereof, wherein said antineoplastic agent and said aromatase inhibitor are present in superadditive antitumor effective amounts.
- 51. (Amended) The pharmaceutical composition according to claim 50, wherein the composition comprises [two antineoplastic agents] <u>epirubicin and docetaxel, and a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, or combinations thereof, and exemestane and a pharmaceutically acceptable carrier, pharmaceutically acceptable diluent or combinations thereof, wherein epirubicin, docetaxel, and exemestane are present in superadditive antitumor effective amounts.</u>
- 52. (Original) The pharmaceutical composition according to claim 50, wherein the antineoplastic agent is epirubicin.
- 53. (Original) The pharmaceutical composition according to claim 50, wherein the antineoplastic agent is docetaxel.
- 54. (Original) The pharmaceutical composition, according to claim 50, wherein an effective antineoplastic amount of epirubicin ranges from about 20 mg/m2 to about 200 mg/m2, and an effective antineoplastic amount of docetaxel ranges from about 50 mg/m to about 100 mg/m.
- 55. (Original) The pharmaceutical composition according to claim 54, wherein when administered orally, the amount of aromatase inhibitor exemestane ranges from about 5 to about 200 mg.
- 56. (Original) The pharmaceutical composition according to claim 55, wherein the amount of aromatase inhibitor exemestane ranges from about 10 to about 25 mg.
- 57. (Original) The pharmaceutical composition according to claim 54, wherein when administered parenterally, the amount of aromatase inhibitor exemestane ranges from about 50 to about 500 mg.
- 58. (Original) The pharmaceutical composition according to claim 50, wherein when administered subcutaneously, the amount of aromatase inhibitor exemestane ranges about 20 mg/Kg/day.
- 59. (Original) The pharmaceutical composition according to claim 58, wherein when administered intravenously, the amount of antineoplastic epirubicin is 1 or 3 mg/Kg/week.

- 60. (Original) The pharmaceutical composition according to claim 58, wherein when administered intravenously, the amount of antineoplastic docetaxel ranges from about 1.5 mg/Kg/week.
- 61. (Original) A method for treating breast cancer in humans, said method comprising administering to a human in need thereof (a) at least one antineoplastic agent selected from the group consisting of epirubicin and docetaxel; and (b) an aromatase inhibitor exemestane, in amounts effective to produce a superadditive antitumor effect.
- 62. (Amended) The method according to claim 61, wherein the method comprising administering [two antineoplastic agents] <u>epirubicin and docetaxel</u>, and a pharmaceutically <u>acceptable carrier</u>, a pharmaceutically <u>acceptable diluent</u>, or <u>combinations thereof</u>, and <u>exemestane and a pharmaceutically acceptable carrier</u>, <u>pharmaceutically acceptable diluent or combinations thereof</u>, <u>wherein epirubicin</u>, <u>docetaxel</u>, <u>and exemestane are present in superadditive antitumor effective amounts</u>.
- 63. (Original) The method according to claim 61, wherein the antineoplastic agent is epirubicin.
- 64. (Original) The method according to claim 61, wherein the antineoplastic agent is docetaxel.
- 65. (Original) The method according to claim 61, wherein an effective antineoplastic amount of epirubicin ranges from about 20 mg/m2 to about 200 mg/m2 and an effective antineoplastic amount of docetaxel ranges from about 50 mg/m2 to about 100 mg/m2.
- 66. (Original) The method according to claim 65, wherein when administered orally, the amount of aromatase inhibitor exemestane ranges from about 5 to about 200 mg.
- 67. (Original) The pharmaceutical composition according to claim 66, wherein the amount of aromatase inhibitor exemestane ranges from about 10 to about 25 mg.
- 68. (Original) The method according to claim 65, wherein when administered parenterally, the amount of aromatase inhibitor exemestane ranges from about 50 to about 500 mg.
- 69. (Original) The method according to claim 61, wherein when administered subcutaneously, the amount of aromatase inhibitor exemestane is about 20 mg/Kg/day.
- 70. (Original) The method according to claim 69, wherein when administered intravenously, the amount of antineoplastic epirubicin is 1 or 3 mg/Kg/week.
- 71. (Original) The method according to claim 69, wherein when administered intravenously, the amount of antineoplastic docetaxel is about 1.5 mg/Kg/week.
- 72. (Original) A method for lowering the side effects in humans caused by breast cancer therapy with an antineoplastic agent, said method comprising administering to a human in need thereof a pharmaceutical composition comprising (a) at least one antineoplastic agent selected from the group consisting of epirubicin and docetaxel; and (b) aromatase inhibitor exemestane, wherein said agent and said inhibitor is present in a quantity to produce a superadditive antitumor effect.
- (Amended) The method according to claim 72, wherein the method comprising